Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort - PubMed (original) (raw)

. 1992 Apr;102(4 Pt 1):1212-9.

Affiliations

PMID: 1551528

Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort

B J Reid et al. Gastroenterology. 1992 Apr.

Abstract

To determine whether or not flow-cytometric evidence of aneuploidy and increased G2/tetraploid fractions predispose to neoplastic progression in Barrett's esophagus, 62 patients with Barrett's esophagus were evaluated prospectively for a mean interval of 34 months. Nine of 13 patients who showed aneuploid or increased G2/tetraploid populations in their initial flow-cytometric analysis developed high-grade dysplasia or adenocarcinoma during follow-up; none of the 49 patients without these abnormalities progressed to high-grade dysplasia or cancer (P less than 0.0001). Neoplastic progression was characterized by progressive flow-cytometric and histological abnormalities. Patients who progressed to high-grade dysplasia and carcinoma frequently developed multiple aneuploid populations of cells that were detectable flow-cytometrically. Similarly, patients appeared to progress through a phenotypic sequence that could be recognized histologically by the successive appearance of Barrett's metaplasia negative for dysplasia, abnormalities in the indefinite/low-grade dysplasia range, high-grade dysplasia, and eventually adenocarcinoma. These and prior results suggest that neoplastic progression in Barrett's esophagus occurs in a subset of patients who have an acquired genomic instability that generates abnormal clones of cells, some of which have aneuploid or increased G2/tetraploid DNA contents. With continued genomic instability, multiple aneuploid subclones may evolve, one of which may ultimately acquire the ability to invade and become an early carcinoma. The combination of histology and flow cytometry can be used to identify a subset of patients with Barrett's esophagus who merit more frequent endoscopic surveillance for the early detection of high-grade dysplasia or carcinoma.

PubMed Disclaimer

Comment in

Barrett's esophagus and adenocarcinoma: from the family to the gene.
Cameron AJ. Cameron AJ. Gastroenterology. 1992 Apr;102(4 Pt 1):1421-4. doi: 10.1016/0016-5085(92)90789-2. Gastroenterology. 1992. PMID: 1551552 No abstract available.

Cited by

Risk Factors for Recurrent Colorectal Polyps.
Hao Y, Wang Y, Qi M, He X, Zhu Y, Hong J. Hao Y, et al. Gut Liver. 2020 Jul 15;14(4):399-411. doi: 10.5009/gnl19097. Gut Liver. 2020. PMID: 31547641 Free PMC article. Review.
Barrett's esophagus.
Ertan A, Younes M. Ertan A, et al. Dig Dis Sci. 2000 Aug;45(8):1670-3. doi: 10.1023/a:1005545918399. Dig Dis Sci. 2000. PMID: 11007123 Review.
Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region.
Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Wu TT, et al. Am J Pathol. 1998 Jul;153(1):287-94. doi: 10.1016/S0002-9440(10)65570-8. Am J Pathol. 1998. PMID: 9665490 Free PMC article.
Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.
van der Burgh A, Dees J, Hop WC, van Blankenstein M. van der Burgh A, et al. Gut. 1996 Jul;39(1):5-8. doi: 10.1136/gut.39.1.5. Gut. 1996. PMID: 8881798 Free PMC article.
Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma.
Oberg S, Wenner J, Johansson J, Walther B, Willén R. Oberg S, et al. Ann Surg. 2005 Jul;242(1):49-54. doi: 10.1097/01.sla.0000167864.46462.9f. Ann Surg. 2005. PMID: 15973101 Free PMC article.

Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort - PubMed (original) (raw)